Table 1.
Peripheral Blood of the WT and Nmp4-KO Mice Was Analyzed Using the Hemavet 950 as Described in the Materials and Method Section
| |
WT |
KO |
2-Way ANOVA P values |
||||
|---|---|---|---|---|---|---|---|
| VEH | PTH | VEH | PTH | Genotype | Treatment | Gene×Treat | |
| Cellularity (106/femur) | 9.1±6.2 | 8.1±5.6 | 14.3±7.1 | 11.5±6.6 | 0.04 | 0.33 | 0.64 |
| % Spleen weight | 0.40±0.03 | 0.47±0.06 | 0.42±0.08 | 0.46±0.07 | 0.84 | 0.01 | 0.49 |
| WBC (K/μL) | 4.8±1.1 | 4.9±1.4 | 4.5±1.6 | 5.6±1.6 | 0.70 | 0.16 | 0.24 |
| NE (K/μL) | 0.70±0.28 | 0.62±0.40 | 0.56±0.32 | 0.73±0.33 | 0.86 | 0.67 | 0.22 |
| NE% | 14.2±3.3 | 12.6±6.1 | 12.7±5.7 | 12.8±4.7 | 0.88 | 0.33 | 0.82 |
| LY (K/μL) | 1.0±0.78 | 4.1±1.1 | 3.7±1.4 | 4.8±1.3 | 0.62 | 0.11 | 0.26 |
| LY% | 82.4±4.3 | 83.8±5.9 | 82.2±8.1 | 84.4±4.8 | 0.88 | 0.33 | 0.82 |
| MO (K/μL) | 0.13±0.05 | 0.14±0.06 | 0.16±0.09 | 0.12±0.03 | 0.89 | 0.53 | 0.21 |
| MO% | 2.7±0.87 | 2.9±1.0 | 3.6±2.1 | 2.2±0.53 | 0.69 | 0.15 | 0.06 |
| EO (IC/μL) | 0.03±0.05 | 0.03±0.04 | 0.04±0.05 | 0.02±0.03 | 0.92 | 0.49 | 0.54 |
| EO% | 0.54±0.88 | 0.56±0.53 | 1.17±1.57 | 0.43±0.52 | 0.42 | 0.24 | 0.23 |
| RBC (M/μL) | 9.6±0.46 | 9.1±1.5 | 8.6±1.2 | 8.8±1.4 | 0.09 | 0.67 | 0.38 |
| PLT (K/μL) | 493.8±124.7 | 486.6±167.4 | 378.9±207.9 | 487.5±142.8 | 0.27 | 0.32 | 0.26 |
WT and null mice were treated with intermittent PTH or vehicle for 3 weeks (number of mice/experimental group=9–14). A 2-factor ANOVA was used to evaluate the impact of genotype and treatment on the individual parameters. Statistical significance was set at P<0.01 to guard against type I errors. Percent (%) spleen weight is the weight of the organ divided by the total body weight.
WT, wild type; VEH, vehicle; PTH, parathyroid hormone; KO, knockout; ANOVA, analysis of variance; EO, eosinophils; LY, lymphocytes; MO, monocytes; NE, neutrophils; PLT, platelets; RBC, red blood cell; WBC, white blood cells.